• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

简明阳性和阴性症状量表(PANSS)的简化版本可行吗?一项批判性综述。

Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.

作者信息

Lindenmayer Jean-Pierre

机构信息

Dr. Lindenmayer is Clinical Professor of the Department of Psychiatry at the NYU School of Medicine in New York, New York.

出版信息

Innov Clin Neurosci. 2017 Dec 1;14(11-12):73-76.

PMID:29410940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5788254/
Abstract

The Positive and Negative Syndrome Scale (PANSS) is a well-established assessment tool for measuring symptom severity in schizophrenia. Researchers and clinicians have been interested in the development of a short version of the PANSS that could reduce the burden of its administration for patients and raters. The author presents a comprehensive overview of existing brief PANSS measures, including their strengths and limitations, and discusses some possible next steps. There are two available scales that offer a reduced number of original PANSS items: PANSS-14 and PANSS-19; and two shorter versions that include six items: Brief PANSS and PANSS-6. The PANSS-6 has been tested quite extensively in established trials and appears to demonstrate high sensitivity to change and an established cut off definition for remission. Prospective testing in new antipsychotic treatment trials is still required for these shorter versions of PANSS. In addition, they need to be supplemented with interview guides, as well as provide conversion formulas to translate total scores from the short PANSS versions to the PANSS-30. Both short versions of the PANSS are essentially designed to evaluate response to antipsychotic treatment. Future PANSS scale development needs to address specific measurement of treatment-responsive positive symptoms by including treatment-sensitive items, as well as illness-phase specific PANSS tools.

摘要

阳性和阴性症状量表(PANSS)是一种成熟的用于测量精神分裂症症状严重程度的评估工具。研究人员和临床医生一直对开发PANSS的简短版本感兴趣,该简短版本可以减轻患者和评估者的施测负担。作者全面概述了现有的简短PANSS测量方法,包括其优点和局限性,并讨论了一些可能的后续步骤。有两种可用的量表减少了原始PANSS项目的数量:PANSS-14和PANSS-19;还有两个较短的版本包含六个项目:简明PANSS和PANSS-6。PANSS-6已在既定试验中进行了广泛测试,似乎对变化具有高敏感性,并且有既定的缓解截止定义。这些较短版本的PANSS仍需要在新的抗精神病药物治疗试验中进行前瞻性测试。此外,它们需要辅以访谈指南,并提供将简短PANSS版本的总分转换为PANSS-30总分的换算公式。两种简短版本的PANSS本质上都是为了评估对抗精神病药物治疗的反应。未来PANSS量表的开发需要通过纳入治疗敏感项目以及疾病阶段特异性PANSS工具来解决对治疗有反应的阳性症状的特定测量问题。

相似文献

1
Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.简明阳性和阴性症状量表(PANSS)的简化版本可行吗?一项批判性综述。
Innov Clin Neurosci. 2017 Dec 1;14(11-12):73-76.
2
PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.PANSS-6:一种用于测量精神分裂症严重程度的简短评定量表。
Acta Psychiatr Scand. 2016 Jun;133(6):436-44. doi: 10.1111/acps.12526. Epub 2015 Nov 12.
3
Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.阳性与阴性症状量表(PANSS)中总体症状缓解与缓解标准之间的差异:一种治疗后双因素项目反应理论模型
Innov Clin Neurosci. 2017 Dec 1;14(11-12):41-53.
4
The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.PANSS-6 在干预有效性临床抗精神病药物试验 (CATIE) 研究中的有效性和敏感性。
Schizophr Bull. 2018 Feb 15;44(2):453-462. doi: 10.1093/schbul/sbx076.
5
Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.理解抗精神病药物治疗效果:一种降低阳性和阴性症状量表(PANSS)因子伪特异性的新方法。
Innov Clin Neurosci. 2017 Dec 1;14(11-12):54-58.
6
Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI).使用简化正负症状访谈(SNAPSI)获得的六项阳性和阴性症状量表(PANSS-6)评分的评分者间信度。
Nord J Psychiatry. 2018 Aug;72(6):431-436. doi: 10.1080/08039488.2018.1492014. Epub 2018 Jul 24.
7
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.首发精神分裂症的严重程度和抗精神病药的疗效:6 项安慰剂对照研究的参与者水平荟萃分析。
JAMA Psychiatry. 2015 Jan;72(1):14-21. doi: 10.1001/jamapsychiatry.2014.2127.
8
Brief PANSS to assess and monitor the overall severity of schizophrenia.简明 PANSS 评估精神分裂症的整体严重程度。
Psychiatry Clin Neurosci. 2010 Jun;64(3):262-7. doi: 10.1111/j.1440-1819.2010.02081.x.
9
Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI).弥合精神分裂症研究与临床护理之间的测量差距:阳性和阴性症状量表-6(PANSS-6)以及基于简化阴性和阳性症状访谈(SNAPSI)的其他评估
Innov Clin Neurosci. 2017 Dec 1;14(11-12):68-72.
10
An excitement subscale of the Positive and Negative Syndrome Scale.阳性和阴性症状量表的兴奋分量表。
Schizophr Res. 2004 Jun 1;68(2-3):331-7. doi: 10.1016/S0920-9964(03)00087-2.

引用本文的文献

1
Replicating and Extending the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials.复制并扩展阳性和阴性症状量表10项版(PANSS10)及阳性和阴性症状量表20项版(PANSS20)在儿科试验中的信度、效标效度及治疗敏感性。
JAACAP Open. 2024 May 23;3(2):257-267. doi: 10.1016/j.jaacop.2024.02.010. eCollection 2025 Jun.
2
Association of neurobiological and immune serum biomarkers with Toxoplasma gondii infection in patients with schizophrenia.精神分裂症患者神经生物学和免疫血清生物标志物与弓形虫感染的关联
Parasitol Res. 2025 May 21;124(5):53. doi: 10.1007/s00436-025-08498-w.
3
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).COSMIN对阳性和阴性症状量表(PANSS)测量属性的系统评价与Meta分析。
EClinicalMedicine. 2025 Apr 11;82:103155. doi: 10.1016/j.eclinm.2025.103155. eCollection 2025 Apr.
4
The perspectives on advance care planning of older people with psychotic illnesses and their carers.患有精神病性疾病的老年人及其照料者对预先护理计划的看法。
Eur Geriatr Med. 2025 Mar 14. doi: 10.1007/s41999-025-01161-8.
5
Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials.复制并扩展缩短版阳性和阴性症状量表在儿科试验中的信度、效标效度及治疗敏感性。
Eur Child Adolesc Psychiatry. 2025 Mar 10. doi: 10.1007/s00787-025-02681-1.
6
The COMPASS scale for the assessment of individuals with first episode psychotic disorders.用于评估首发精神性障碍个体的COMPASS量表。
Schizophr Res. 2024 Dec;274:307-314. doi: 10.1016/j.schres.2024.10.009. Epub 2024 Oct 21.
7
Extension and Further Replication of the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials.PANSS10和PANSS20在儿科试验中的信度、效标效度及治疗敏感性的扩展与进一步验证
J Child Adolesc Psychopharmacol. 2024 Dec;34(10):447-457. doi: 10.1089/cap.2024.0078. Epub 2024 Oct 17.
8
Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis.奥氮平-沙米多芬治疗精神分裂症:系统评价与荟萃分析
Indian J Psychol Med. 2024 Jan;46(1):14-23. doi: 10.1177/02537176231201326. Epub 2023 Oct 22.
9
Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.阳性和阴性症状量表(PANSS)-30、其主要子量表加 PANSS-6 的初始严重程度,以及与随后的改善和试验脱落的关系:18 项安慰剂对照利培酮和帕利哌酮试验的汇总参与者水平分析。
Transl Psychiatry. 2023 Jun 7;13(1):191. doi: 10.1038/s41398-023-02491-6.
10
Fibre density and fibre-bundle cross-section of the corticospinal tract are distinctly linked to psychosis-specific symptoms in antipsychotic-naïve patients with first-episode schizophrenia.皮质脊髓束的纤维密度和纤维束横截面积与首发精神分裂症抗精神病药物初治患者的精神病特异性症状明显相关。
Eur Arch Psychiatry Clin Neurosci. 2023 Dec;273(8):1797-1812. doi: 10.1007/s00406-023-01598-7. Epub 2023 Apr 4.

本文引用的文献

1
The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.PANSS-6 在干预有效性临床抗精神病药物试验 (CATIE) 研究中的有效性和敏感性。
Schizophr Bull. 2018 Feb 15;44(2):453-462. doi: 10.1093/schbul/sbx076.
2
PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.PANSS-6:一种用于测量精神分裂症严重程度的简短评定量表。
Acta Psychiatr Scand. 2016 Jun;133(6):436-44. doi: 10.1111/acps.12526. Epub 2015 Nov 12.
3
On the use of the Positive and Negative Syndrome Scale in randomized clinical trials.关于正负症状量表在随机临床试验中的应用。
Schizophr Res. 2015 Jul;165(2-3):181-7. doi: 10.1016/j.schres.2015.04.006. Epub 2015 May 1.
4
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.探索精神分裂症阳性与阴性症状量表五因素模型的共识。
Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
5
Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS).运用非参数项目反应理论开发简明版阳性与阴性症状量表(PANSS)。
BMC Psychiatry. 2011 Nov 16;11:178. doi: 10.1186/1471-244X-11-178.
6
Comparing the PANSS in Chinese and American inpatients: cross-cultural psychiatric analyses of instrument translation and implementation.比较中美住院患者的 PANSS:工具翻译和实施的跨文化精神病学分析。
Schizophr Res. 2011 Nov;132(2-3):146-52. doi: 10.1016/j.schres.2011.08.003. Epub 2011 Sep 1.
7
Brief PANSS to assess and monitor the overall severity of schizophrenia.简明 PANSS 评估精神分裂症的整体严重程度。
Psychiatry Clin Neurosci. 2010 Jun;64(3):262-7. doi: 10.1111/j.1440-1819.2010.02081.x.
8
Item response analysis of the Positive and Negative Syndrome Scale.阳性和阴性症状量表的项目反应分析
BMC Psychiatry. 2007 Nov 15;7:66. doi: 10.1186/1471-244X-7-66.
9
Alpha if item deleted: a note on loss of criterion validity in scale development if maximizing coefficient alpha.如果删除项目时的α系数:关于在量表编制中为使α系数最大化而导致效标效度丧失的一则说明。
Br J Math Stat Psychol. 2008 Nov;61(Pt 2):275-85. doi: 10.1348/000711007X188520. Epub 2007 Apr 12.
10
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.阳性和阴性症状量表的五因素模型I:验证性因素分析未能证实25种已发表的五因素解决方案。
Schizophr Res. 2006 Jul;85(1-3):273-9. doi: 10.1016/j.schres.2006.04.001. Epub 2006 May 26.